[HTML][HTML] Translational advances in pancreatic ductal adenocarcinoma therapy

AN Hosein, SK Dougan, AJ Aguirre, A Maitra - Nature cancer, 2022 - nature.com
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer that is most frequently
detected at advanced stages, limiting treatment options to systemic chemotherapy with …

Pancreatic cancer: pathogenesis, screening, diagnosis, and treatment

LD Wood, MI Canto, EM Jaffee, DM Simeone - Gastroenterology, 2022 - Elsevier
Pancreatic ductal adenocarcinoma (PDAC) is a clinically challenging cancer, due to both its
late stage at diagnosis and its resistance to chemotherapy. However, recent advances in our …

Single-nucleus and spatial transcriptome profiling of pancreatic cancer identifies multicellular dynamics associated with neoadjuvant treatment

WL Hwang, KA Jagadeesh, JA Guo, HI Hoffman… - Nature …, 2022 - nature.com
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal and treatment-refractory
cancer. Molecular stratification in pancreatic cancer remains rudimentary and does not yet …

[HTML][HTML] Ordered and deterministic cancer genome evolution after p53 loss

T Baslan, JP Morris IV, Z Zhao, J Reyes, YJ Ho… - Nature, 2022 - nature.com
Although p53 inactivation promotes genomic instability and presents a route to malignancy
for more than half of all human cancers,, the patterns through which heterogenous TP53 …

Pancreatic cancer evolution and heterogeneity: integrating omics and clinical data

AA Connor, S Gallinger - Nature Reviews Cancer, 2022 - nature.com
Pancreatic ductal adenocarcinoma (PDAC), already among the deadliest epithelial
malignancies, is rising in both incidence and contribution to overall cancer deaths. Decades …

[HTML][HTML] MACHETE identifies interferon-encompassing chromosome 9p21. 3 deletions as mediators of immune evasion and metastasis

FM Barriga, KM Tsanov, YJ Ho, N Sohail, A Zhang… - Nature Cancer, 2022 - nature.com
The most prominent homozygous deletions in cancer affect chromosome 9p21. 3 and
eliminate CDKN2A/B tumor suppressors, disabling a cell-intrinsic barrier to tumorigenesis …

Selective multi-kinase inhibition sensitizes mesenchymal pancreatic cancer to immune checkpoint blockade by remodeling the tumor microenvironment

C Falcomata, S Baerthel, SA Widholz, C Schneeweis… - Nature Cancer, 2022 - nature.com
KRAS-mutant pancreatic ductal adenocarcinoma (PDAC) is highly immunosuppressive and
resistant to targeted and immunotherapies. Among the different PDAC subtypes, basal-like …

[HTML][HTML] Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine

X Huang, G Zhang, TY Tang, X Gao, TB Liang - Military Medical Research, 2022 - Springer
Pancreatic cancer is characterized by inter-tumoral and intra-tumoral heterogeneity,
especially in genetic alteration and microenvironment. Conventional therapeutic strategies …

GREM1 is required to maintain cellular heterogeneity in pancreatic cancer

L Lan, T Evan, H Li, A Hussain, EJ Ruiz, M Zaw Thin… - Nature, 2022 - nature.com
Pancreatic ductal adenocarcinoma (PDAC) shows pronounced epithelial and mesenchymal
cancer cell populations,,–. Cellular heterogeneity in PDAC is an important feature in disease …

[HTML][HTML] Integrated profiling of human pancreatic cancer organoids reveals chromatin accessibility features associated with drug sensitivity

X Shi, Y Li, Q Yuan, S Tang, S Guo, Y Zhang… - Nature …, 2022 - nature.com
Chromatin accessibility plays an essential role in controlling cellular identity and the
therapeutic response of human cancers. However, the chromatin accessibility landscape …